Health-Related Quality of Life Across the Spectrum of Pulmonary Hypertension

被引:1
作者
Balasubramanian, Aparna [1 ]
Larive, A. Brett [2 ]
Horn, Evelyn M. [6 ]
DuBrock, Hilary M. [7 ]
Mehra, Reena [3 ]
Jacob, Miriam S. [4 ]
Hemnes, Anna R. [9 ]
Leopold, Jane A. [10 ]
Radeva, Milena K. [2 ]
Hill, Nicholas S. [11 ]
Erzurum, Serpil C. [5 ]
Rosenzweig, Erika B. [12 ]
Frantz, Robert P. [8 ]
Rischard, Franz P. [13 ]
Beck, Gerald J. [2 ]
Hassoun, Paul M. [1 ]
Mathai, Stephen C. [1 ]
机构
[1] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MA 21218 USA
[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA
[3] Cleveland Clin, Neurol & Resp Inst, Cleveland, OH USA
[4] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH USA
[5] Cleveland Clin, Lerner Res Inst, Cleveland, OH USA
[6] Weill Cornell Med, Div Cardiol, New York, NY USA
[7] Mayo Clin, Dept Pulm & Crit Care Med, Rochester, MN USA
[8] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA
[9] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN USA
[10] Harvard Med Sch, Womens Hosp, Div Cardiovasc Med Brigham, Boston, MA USA
[11] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA USA
[12] Columbia Univ, Dept Pediat & Med, New York, NY USA
[13] Univ Arizona, Div Pulm Allergy Crit Care & Sleep Med, Tucson, AZ USA
基金
美国国家卫生研究院;
关键词
health-related quality of life; pulmonary hypertension; ARTERIAL-HYPERTENSION; DOUBLE-BLIND; QUESTIONNAIRE; SURVIVAL; DISEASE; PROSTACYCLIN; MULTICENTER; VALIDATION; SILDENAFIL; EFFICACY;
D O I
10.1016/j.chest.2024.02.009
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Health-related quality of life (HRQOL) is frequently impaired in pulmonary arterial hypertension. However, little is known about HRQOL in other forms of pulmonary hypertension (PH). RESEARCH QUESTION: Does HRQOL vary across groups of the World Symposium on Pulmonary Hypertension (WSPH) classification system? STUDY DESIGN AND METHODS: This cross-sectional study included patients with PH from the Pulmonary Vascular Disease Phenomics (PVDOMICS) cohort study. HRQOL was assessed by using emPHasis-10 (e-10), the 36-item Medical Outcomes Study Short Form survey (physical component score [PCS] and mental component score), and the Minnesota Living with Heart Failure Questionnaire. Pearson correlations between HRQOL and demographic, physiologic, and imaging characteristics within each WSPH group were tested. Multivariable linear regressions compared HRQOL across WSPH groups, adjusting for demographic characteristics, disease prevalence, functional class, and hemodynamics. Cox proportional hazards models were used to assess associations between HRQOL and survival across WSPH groups. RESULTS: Among 691 patients with PH, HRQOL correlated with functional class and 6-min walk distance but not hemodynamics. HRQOL was severely depressed across WSPH groups for all measures except the 36-item Medical Outcomes Study Short Form survey mental component score. Compared with Group 1 participants, Group 2 participants had significantly worse HRQOL (e-10 score, 29 vs 24 [P = .001]; PCS, 32.9 + 8 vs 38.4 + 10 [P < .0001]; and Minnesota Living with Heart Failure Questionnaire score, 50 vs 38 [P = .003]). Group 3 participants similarly had a worse e-10 score (31 vs 24; P < .0001) and PCS (33.3 + 9 vs 38.4 + 10; P < .0001) compared with Group 1 participants, which persisted in multivariable models (P < .05). HRQOL was associated in adjusted models with survival across Groups 1, 2, and 3. INTERPRETATION: HRQOL was depressed in PH and particularly in Groups 2 and 3 despite less severe hemodynamics. HRQOL is associated with functional capacity, but the severity of hemodynamic disease poorly estimates the impact of PH on patients' lives. Further studies are needed to better identify predictors and treatments to improve HRQOL across the spectrum of PH.
引用
收藏
页码:1493 / 1504
页数:12
相关论文
共 43 条
  • [1] [Anonymous], 2000, MEAS HLTH DAYS
  • [2] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
    Barst, RJ
    Rubin, LJ
    Long, WA
    McGoon, MD
    Rich, S
    Badesch, DB
    Groves, BM
    Tapson, VF
    Bourge, RC
    Brundage, BH
    Koerner, SK
    Langleben, D
    Keller, CA
    Murali, S
    Uretsky, BF
    Clayton, LM
    Jobsis, MM
    Blackburn, SD
    Shortino, D
    Crow, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) : 296 - 301
  • [3] Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients
    Bonner, Nicola
    Abetz, Linda
    Meunier, Juliette
    Sikirica, Mirko
    Mathai, Stephen C.
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
  • [4] Borgese M, 2021, Eur Respir J, V57
  • [5] Measurement of quality of life in pulmonary hypertension and its significance
    Cenedese, E.
    Speich, R.
    Dorschner, L.
    Ulrich, S.
    Maggiorini, M.
    Jenni, R.
    Fischler, M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (04) : 808 - 815
  • [6] Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
    Chebib, Nader
    Mornex, Jean-Francois
    Traclet, Julie
    Philit, Francois
    Khouatra, Chahera
    Zeghmar, Sabrina
    Turquier, Segolene
    Cottin, Vincent
    [J]. PULMONARY CIRCULATION, 2018, 8 (02)
  • [7] Psychometric Validation of the Pulmonary Arterial Hypertension- Symptoms and Impact (PAH-SYMPACT) Questionnaire Results of the SYMPHONY Trial
    Chin, Kelly M.
    Gomberg-Maitland, Mardi
    Channick, Richard N.
    Cuttica, Michael J.
    Fischer, Aryeh
    Frantz, Robert P.
    Hunsche, Elke
    Kleinman, Leah
    McConnell, John W.
    McLaughlin, Vallerie V.
    Miller, Chad E.
    Zamanian, Roham T.
    Zastrow, Michael S.
    Badesch, David B.
    [J]. CHEST, 2018, 154 (04) : 848 - 861
  • [8] Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with chronic thromboembolic pulmonary hypertension (CTEPH): a qualitative interview study
    Currie, Brooke
    Davies, Evan
    Beaudet, Amelie
    Stassek, Larissa
    Kleinman, Leah
    [J]. JOURNAL OF PATIENT-REPORTED OUTCOMES, 2021, 5 (01)
  • [9] Pulmonary arterial hypertension: the burden of disease and impact on quality of life
    Delcroix, Marion
    Howard, Luke
    [J]. EUROPEAN RESPIRATORY REVIEW, 2015, 24 (138) : 621 - 629
  • [10] Quality of life as a prognostic marker in pulmonary arterial hypertension
    Fernandes, Caio J. C. S.
    Martins, Barbara C. S.
    Jardim, Carlos V. P.
    Ciconelli, Rozana M.
    Morinaga, Luciana K.
    Breda, Ana Paula
    Hoette, Susana
    Souza, Rogerio
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2014, 12